Resistant Arterial Hypertension Cohort Study

Hypertension Clinical Trial

— RAHyCo  

Official title:

Interventional Prospective Cohort Study, Multi-center With Nested Case-control Studies (Family-based and Non-family Based) on Individuals With Resistant Arterial Hypertension.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01083017
• Other study ID #: RAHyCOstudy
• Secondary ID: 33CM30-124087CER
• Status: Completed
• Start date: April 2011
• Est. completion date: May 2017

Study information

• Verified date: October 2018
• Source: University Hospital, Geneva
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to investigate the epidemiology of resistant hypertension, evaluate the efficacy and feasibility of a standardized drug treatment regimen (including the randomization of two doses of the diuretic used - chlorthalidone), study two interventions in the group of patients that is non-compliant, and study environmental and genetic variables of individuals with resistant hypertension in a family design.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 74
• Est. completion date: May 2017
• Est. primary completion date: May 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• informed consent

• resistant hypertension at the moment of inclusion

• 18 years or more, both sexes are included

• women at reproductive age: consenting to use oral contraception

Exclusion Criteria:

• patients mentally impaired or unable to give informed consent

• patients speaking only a foreign language other than French, German, or English

• patients living far away, making the study visits not practical

Related Conditions & MeSH terms

• Essential Hypertension
• Hypertension
• Resistant Hypertension

Intervention

Drug:
• chlorthalidone
chlorthalidone 25mg/d vs. chlorthalidone 50mg/d

Behavioral:
• motivational intervention for non-compliant individuals
motivational interview(s) vs. repeated calls vs. no particular intervention

Drug:
• standardized anti-hypertensive treatment
olmesartan, amlodipine, chlorthalidone, +- spironolactone

Locations

Country	Name	City	State
Switzerland	Geneva University Hospitals	Geneva
Switzerland	Lausanne University Hospital, CHUV	Lausanne
Switzerland	Kantonsspital Luzern	Luzern

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Geneva

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	blood pressure control		at 12 weeks after initiation of standard treatment
Secondary	cardiovascular morbidity and mortality	additional secondary: BP control at yearly follow-up	5 years